Online citations, reference lists, and bibliographies.
← Back to Search

New Approach To Improve Encapsulation And Antitumor Activity Of Doxorubicin Loaded In Solid Lipid Nanoparticles.

S. Mussi, R. C. Silva, M. Oliveira, C. M. Lucci, R. B. Azevedo, L. A. Ferreira
Published 2013 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This work aimed to develop solid lipid nanoparticles (SLNs) loaded with doxorubicin evaluating the influence of docosahexaenoic acid (DHA), a polyunsaturated fatty acid that enhances the activity of anticancer drugs, on drug encapsulation efficiency (EE). The SLN were characterized for size, zeta potential, entrapment efficiency (EE) and drug release. Studies of in vitro antitumor activity and cellular uptake were also conducted. The reduction in particle size (from 127 ± 14 to 94 ± 1 nm) and negative charges were obtained for SLN loaded with DHA and triethanolamine (TEA), amine used to increase the solubility of doxorubicin in melted lipid. The EE was significantly improved from 36 ± 4% to 99 ± 2% for SLN without and with DHA at 0.4%, respectively. The doxorubicin release in a slightly acid medium (pH 5.0) was higher than that observed at physiological pH. The in vitro studies clearly showed the higher cytotoxicity of doxorubicin-DHA-loaded SLN than free doxorubicin+DHA on human lung tumor cell line (A549) and the improved cellular uptake achieved with the drug encapsulation can be an explanation. These findings suggest that DHA-doxorubicin-loaded SLN is a promising alternative for the treatment of cancer.
This paper references
10.1016/j.ejpb.2008.11.010
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
H. Maeda (2009)
10.1002/JPS.20100
Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers.
H. L. Wong (2004)
10.1016/j.ijpharm.2012.04.050
Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES).
A. Siddiqui (2012)
10.1007/s11095-006-0282-x
A New Polymer–Lipid Hybrid Nanoparticle System Increases Cytotoxicity of Doxorubicin Against Multidrug-Resistant Human Breast Cancer Cells
H. L. Wong (2006)
10.1016/S0378-5173(00)00562-7
Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel.
A. Miglietta (2000)
10.1111/j.2042-7158.2010.01024.x
Lipid nanoparticles for the delivery of poorly water‐soluble drugs
H. Bunjes (2010)
10.1016/J.EJPB.2006.10.022
In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
H. L. Wong (2007)
10.1002/IJC.2910400625
Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin‐sensitive and ‐resistant small‐cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines
J. G. Zulstra (1987)
10.1046/J.1523-1755.1998.00202.X
Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line.
E. Healy (1998)
10.1124/jpet.106.101154
A Mechanistic Study of Enhanced Doxorubicin Uptake and Retention in Multidrug Resistant Breast Cancer Cells Using a Polymer-Lipid Hybrid Nanoparticle System
H. L. Wong (2006)
10.1038/nrd3373
Cell death assays for drug discovery
O. Kepp (2011)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1093/JNCI/DJM135
Drug resistance and the solid tumor microenvironment.
O. Trédan (2007)
10.1007/BF00262767
Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product
S. Ozawa (2004)
10.1016/J.FREERADBIOMED.2005.04.023
Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation.
K. Mahéo (2005)
10.1158/1078-0432.CCR-06-0386
Sensitization by Dietary Docosahexaenoic Acid of Rat Mammary Carcinoma to Anthracycline: A Role for Tumor Vascularization
S. Colas (2006)
10.1016/j.ejps.2009.04.008
Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin.
Robhash Kusam Subedi (2009)
10.1002/biof.181
Docosahexaenoic acid: a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects.
R. Siddiqui (2011)
10.1016/j.ijpharm.2009.07.025
Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles.
Gisele A. Castro (2009)
10.1016/j.dental.2009.10.005
Influence of TEGDMA on the mammalian cell cycle in comparison with chemotherapeutic agents.
A. Eckhardt (2010)
10.1016/j.addr.2011.04.006
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.
Yinghuan Li (2012)
10.1006/PHRS.2000.0695
Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats.
A. Fundaró (2000)
10.1158/1078-0432.CCR-05-1664
The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors
Andrew J Primeau (2005)
10.1002/(SICI)1097-0215(19980209)75:4<578::AID-IJC14>3.0.CO;2-5
Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MBA‐MB‐231: Relationship to lipid peroxidation
E. Germain (1998)
10.1016/j.yjmcc.2012.03.006
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
Yanti Octavia (2012)
10.1038/sj.bjc.6605441
Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial
P. Bougnoux (2009)
10.1002/CYTO.990130802
Features of apoptotic cells measured by flow cytometry.
Z. Darzynkiewicz (1992)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1016/S0378-4347(98)00475-7
High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues.
L. Alvarez-Cedrón (1999)
10.1006/PHRS.1999.0509
Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN).
G. Zara (1999)
10.1016/j.addr.2010.03.011
Tumor delivery of macromolecular drugs based on the EPR effect.
V. Torchilin (2011)
Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts.
W. Hardman (2001)
10.1166/JBN.2009.1021
Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.
P. Ma (2009)
10.1016/J.EJPB.2004.03.026
Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line.
L. Serpe (2004)
10.1021/mp8000759
Poly(vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the alpha-modification.
K. Rosenblatt (2009)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)



This paper is referenced by
10.1016/j.jcis.2020.08.045
Internal liquid crystal structures in nanocarriers containing drug hydrophobic ion pairs dictate drug release.
Kurt Ristroph (2020)
10.1016/j.ijpharm.2018.05.070
Nanostructured lipid carriers‐based drug delivery for treating various lung diseases: A State‐of‐the‐Art Review
Tulshidas S Patil (2018)
10.1039/C3TB20990C
Recent trends in the use of lipidic nanoparticles as pharmaceutical carriers for cancer therapy and diagnostics.
S. Mussi (2013)
10.1016/J.CEJ.2014.02.041
Design of soft lipid nanocarriers based on bioactive vegetable oils with multiple health benefits
I. Lăcătuşu (2014)
10.1039/c9na00308h
Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers
Kurt Ristroph (2019)
10.3109/03639045.2014.972412
In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract
V. Jannin (2015)
10.4155/ebo.13.331
Solid lipid nanoparticles: a current approach to new drug-delivery systems in nanotechnology
Sonia Dhiman (2013)
10.4155/tde-2019-0072
Omega-3 fatty acids as adjunctive therapeutics: prospective of nanoparticles in its formulation development.
M. Ahmad (2019)
10.2174/1573413714666180809120435
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review of the Effect of Physicochemical Formulation Factors in the Optimization Process, Different Preparation Technique, Characterization, and Toxicity
G. Poovi (2019)
10.2217/nnm-2017-0202
The use of nanoparticulates to treat breast cancer.
Xiaomeng Tang (2017)
10.2174/0929867325666181116143713
Development of topical nanocarriers for skin cancer treatment using Quality by Design approach.
E. Csányi (2018)
10.3390/nano8121022
Development of Pranoprofen Loaded Nanostructured Lipid Carriers to Improve Its Release and Therapeutic Efficacy in Skin Inflammatory Disorders
M. Rincón (2018)
10.1080/1061186X.2017.1380655
Advances in nano-delivery systems for doxorubicin: an updated insight
Ummarah Kanwal (2018)
10.1016/j.msec.2015.06.019
Lipid nanocarriers based on natural oils with high activity against oxygen free radicals and tumor cell proliferation.
I. Lăcătuşu (2015)
10.1016/J.TETLET.2016.11.118
NMR analysis of antitumor drugs: Doxorubicin, daunorubicin and their functionalized derivatives
Kinga Piorecka (2017)
10.1021/la502977j
Ursolic acid incorporation does not prevent the formation of a non-lamellar phase in pH-sensitive and long-circulating liposomes.
Sávia C. A. Lopes (2014)
10.1002/2211-5463.12359
Comparison of a new nanoform of the photosensitizer chlorin e6, based on plant phospholipids, with its free form
L. V. Kostryukova (2018)
Polymer and Lipid-based Nanomedicine of Synergistic Drug Combination for Improving Chemotherapy of Multidrug Resistant Breast Cancer
Rui Xue Zhang (2016)
10.1016/j.ijpharm.2015.08.079
Improved pharmacokinetics and enhanced tumor growth inhibition using a nanostructured lipid carrier loaded with doxorubicin and modified with a layer-by-layer polyelectrolyte coating.
S. Mussi (2015)
10.3109/21691401.2015.1129616
Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers
T. H. Tran (2016)
10.1016/J.INDCROP.2018.07.044
The incorporation of Pterodon pubescens fruit oil into optimized nanostructured lipid carriers improves its effectiveness in colorectal cancer
P. M. Outuki (2018)
10.1208/s12249-016-0693-x
Membrane-Loaded Doxorubicin Liposomes Based on Ion-Pairing Technology with High Drug Loading and pH-Responsive Property
H. Xu (2016)
10.5539/JFR.V3N4P3
Novel Neuroprotective Formulations Based on St. John’s Wort Extract
M. Vazzana (2014)
10.18097/PBMC20176301056
Влияние включения доксорубицина в фосфолипидные наночастицы на накопление в опухоли и специфическую активность
Наталья Велориковна Медведева (2017)
10.1016/j.canlet.2016.12.012
Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells.
Y. González-Fernández (2017)
Nanoformulation for anticancer drug delivery: Enhanced pharmacokinetics and circulation
Gaurav Parekh (2015)
10.15171/apb.2015.022
Solid Lipid Nanoparticles as Efficient Drug and Gene Delivery Systems: Recent Breakthroughs.
Jafar Ezzati Nazhad Dolatabadi (2015)
10.1016/j.colsurfb.2014.01.055
Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles.
Jafar Ezzati Nazhad Dolatabadi (2014)
LIPID NANOPARTICLES: APPLICATION IN CANCER THERAPY
S. M. Salunkhe (2014)
10.18097/PBMC2017630156
[Influence of doxorubicin inclusion into phospholipid nanoparticles on tumor accumulation and specific activity].
N. V. Medvedeva (2017)
10.2147/IJN.S197499
Nanomedicine-based formulations containing ω-3 polyunsaturated fatty acids: potential application in cardiovascular and neoplastic diseases
S. Serini (2019)
10.1016/j.ejpb.2014.02.005
Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers - a systematic review of in vitro data.
S. Doktorovová (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar